Mizuho n Acadia Pharmaceuticals (ACAD): 'we view risk/reward as skewed significantly to the upside'
Tweet Send to a Friend
Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
